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Tissue engineering is a newly emerging field targeting many unresolved health problems. So far, the 
achievements of this technology in the production of different tissue engineered substitutes were 
promising. This review is intended to describe, briefly and in a simple language, what tissue 
engineering is, what the achievements of this technology are, what the market volume for its products 
is, what knowledge is needed for practice of this science, how different countries approached this field, 
and the effects of tissue engineering on national development. This report is primarily written to raise 
awareness of health authorities and policy makers in developing countries to this technology and help 
them to approach this multidisciplinary field in a proper way.  
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As a tissue engineering graduate, I was expected by 
health authorities and policy makers to describe the 
usefulness and applications of this newly emerging field, 
and show how it can help the health system in a 
developing country. The authorities were interested to 
know the achievements of this field, the potential market 
volume, and the impact of tissue engineering on the 
national development. Although, many in-depth studies 
have been performed on different aspects of tissue 
engineering by various national and international commi-
ttees, a concise, and yet comprehensive report has not 
been published so far to address the above issues for 
health policy makers of developing countries. Using the 
data of previous comprehensive studies, this review is 
aimed to bringing the technology of tissue engineering to 
the attention of busy health authorities of developing 
countries and helping them to understand what tissue 
engineering is, and how it could be approached.  
Despite modern advances in the fields of medicine and 
surgery, the problem of tissue loss and its consequent 
functional impairment is still considered one of the major 
challenges for practicing physicians. The oldest available 
description of a method for replacement of a lost tissue 
dates back to a thousand years BC when an Indian 
surgeon reconstructed the cut nose of a patient with the 
skin of his forehead (Grikscheit and Vacanti, 2002). 
Currently, five different strategies are employed for re-
placing the lost tissues: (1) Replacement of the lost tissue 
with a tissue from another part of the body, e.g. 
replacement of a lost thumb with big toe. This strategy is 
not applicable for all cases, for example a myocardium 
cannot be replaced by another tissue. (2) Replacement 
with artificial materials e.g. replacement of aortic artery 
with Dacron. The problem is the artificial material may not 
be able to adapt properly with all the physiological 
conditions. Also, in a young patient in growing age, the 
material may not be able to increase its size 
proportionate to the growth of the body. (3) Xenograft or 
allografts are other approaches. The problems with these 
methods are their limited availability and immunological 
incompatibility. (4) Use of an artificial device such as 
hemodialyzder to restore the lost physiological function. 
But, the limitations in continuous use of the device and 
the limited potential to adapt to all physiological needs of 
the body in different conditions are of major concerns. (5) 
Employment of living cells to replace the lost tissue, 
which is the basis of tissue engineering.  
The term tissue engineering was officially defined in a 
National Science Foundation (NSF) workshop (USA) in 
1988 as “the application of principles and methods of 
engineering and life sciences toward fundamental under-
standing of structure-function relationships in normal and  




pathological mammalian tissues and the development of 
of biological substitutes to restore, maintain or improve 
tissue function” (Skalak and Fox, 1988). For legislative 
purposes, in 2005, European Commission Directorate 
General for Enterprise and Industry proposed recognition 
of cells and tissues as “engineered” if they fulfil one of the 
following criteria: (1) the cells or tissues that have been 
subjected to substantial manipulation, so that their 
original biological characteristics, physiological functions 
or structural properties relevant for the intended 
regeneration, repair or replacement, are altered. 
Manipulations such as cutting, grinding, shaping, 
centrifugation, soaking in antimicrobial solutions, 
sterilization, irradiation, cell separation, centrifugation or 
purification, filtering, lyophilization, freezing, 
cryopreservation, and vitrification are not considered as 
substantial. (2) The cells or tissues are not intended to be 
used for the same essential function or functions in the 
recipient as in the donor. (3) The cells or tissues form 
part of a combined advanced therapy medicinal product 
(Anon, 2005c).  
The intention of the field of tissue engineering, which is 
also called regenerative medicine, is to produce living 
substitutes using live cells, usually in an interactive 
environment with biomaterials. These substitutes are 
aimed to have the potential to proliferate and adapt mor-
phologically and functionally to their transplanted 
environment. The complexities of manufacturing of such 
products necessitate a multidisciplinary effort and interac-
tion between the fields of medicine, biomaterials, cellular 
and molecular biology, and even nanotechnology.  
Tissue engineering and regenerative medicine can 
help to improve the quality of healthcare in a wide range 
of non-communicable health problems. Non-
communicable diseases need special attention in 
developing countries. In the 2003 report of WHO it has 
been pointed out that these diseases were ignored in 
developing countries (Anon, 2003b). It is estimated that 
by 2020, 70% of deaths will be caused by non-
communicable diseases in these countries (Boutayeb 
and Boutayeb, 2005). The point is the conditions that are 
currently considered as tissue engineering targets are 
more prevalent in developing countries (Hofman et al., 
2005; Folch et al., 2003; Jamison et al., 2006). For 
example 80% of the world mortalities due to chronic 
diseases (Anon, 2005b) and 90% of the world mortalities 
following traumatic injuries (Hofman et al., 2005; Jamison 
et al., 2006) occur in the developing countries.  
 
 
ACHIEVEMENTS OF TISSUE ENGINEERING 
 
Several years of scientific efforts in different countries 
have led to the manufacturing of several tissue 
engineered products, which either have passed all the 
regulatory issues and gained access to the healthcare 
markets or are still in the clinical trial phase. The main 





Tissue engineered skin products 
 
These products are indicated for use in burns injury 
(Jones et al., 2002), chronic ulcers (Harding et al., 2002), 
and cosmetic surgery. The first skin products were 
manufactured for treatment of burns victims. These pro-
ducts include: Integra (Integra Lifesciences Corporation, 
USA), (Heimbach et al., 2003; Winfrey et al., 1999) Epicel 
(Genzyme Biosurgery, USA) (Wright et al., 1998; 
Compton et al., 1989), and TransCyte (Smith and 
Nephew, UK) (Kumar et al., 2004; Noordenbos et al., 
1999). Due to higher rate of chronic skin ulcers, the 
commercial value of the products that are licensed for 
treatment of this condition is higher than others (Jones et 
al., 2002). Therefore, various products are available for 
management of chronic skin ulcers including Apligraf 
(Organogenesis, USA) (Eaglstein and Falanga, 1997; 
Cavorsi et al., 2006; Curran and Plosker, 2002), 
Dermagraft (Smith and Nephew, UK and Advanced 
Tissue Sciences, USA) (Marston, 2004; Omar et al., 
2004; Gentzkow et al., 1996), EpiDex (Euroderm, 
Germany) (Tausche et al., 2003), Epibase (Laboratoires 
Genévrier, France) (Vaillant, 2002; Soler, 2002), Myskin 
(CellTran, UK) (Moustafa et al., 2004), OrCel (Ortec, 
USA) (Still et al., 2003), BioSeed-S (BioTissue Techno-
logies, Germany) (Johnsen et al., 2005), Hyalograft 3D, 
and Laserskin, (all by Fidia Advanced Biopolymers, Italy) 
(Caravaggi et al., 2003). The products that are marketed 
for cosmetic surgery applications include BioSeed-M 
(BioTissue Technologies AG, 2002) and MelanoSeed 
(both by BioTissue Technologies AG, Germany) 
(Westerhof et al., 2001). 
 
 
Tissue engineered cartilage products 
 
These products are aimed to repair cartilage defects, 
especially in lower extremities. Cartilage defects, espe-
cially in the knee joint, lead to erosion of articular 
surfaces and painful movement of the affected knee. In 
case of extensive degeneration of the joint, prosthetic 
replacement will be necessary. Application of tissue 
engineered cartilage products to the site of defect causes 
regeneration and obviates the need for major surgical 
operations. Current products are obtained by in vitro 
proliferation of autologous chondrocytes including Carti-
cel (Genzyme Biosurgery, USA) (Beary III et al., 1998), 
Hyalograft C (Fidia Advanced Biopolymers, Italy) 
(Marcacci et al., 2005), Matrix-induced Autologous 
Chondrocyte Implantation (MACI) (Verigen, Germany) 
(Vibe-Hansen and Aesculai, 1998), ChondroArt (Educell, 
Slovenia) (Drobnic et al., 2002), co.don chondrotrans-
plant (Grifka et al., 2000) and co.don chondrosphere (the 
latter is marketed as ARTHROcell as well) (both by 
co.don, Germany) (Litzke et al., 2004), BioSeed-C 
(BioTissue Technologies, Germany) (Erggelet et al., 





al., 2005; Gaissmaier et al., 2006), Cartilage Repair 
System (CaReS) (Arthro Kinetics, Germany) (Andereya 
et al., 2006), ArthroMatrix, which is also marketed as 
Chondrokin (Orthogen, Germany) (Anon., 2002a), 
ChondroTec (CellTec, Germany) (Anon, 2001a), and 
ChondroCelect (TiGenix, Belgium) (Vanlauwe, 2005).  
 
 
Tissue engineered bone products 
 
These products are used for treatment of remaining 
defects after extensive fractures, surgical operations for 
bone tumours and plastic maxillofacial surgeries. The 
advantage of tissue engineered products over prostheses 
that do not biologically interact with the bone tissue is 
their ability to increase the rate and quality of healing. 
These products include BioSeed-Oral Bone (BioTissue 
Technologies, Germany) (Strietzel, 2006; Schmelzeisen 
et al., 2003), co.don osteotransplant (co.don, Germany) 
(Bobic, 2000), and Osteocel, an allograft with proprietary 




Tissue engineered vascular products 
 
These products are in the clinical trial stage and are 
aimed to be used to replace coronary heart and 
peripheral vessels. These trials are conducted by co.don 
(Germany) (the products are Vascuplant (Josimovic´-
Alasevic´ and Fritsch, 2001) and Vascular Biotech (Lamm 
et al., 2003)), the Heart Institute of Japan (Matsumura et 
al., 2003; Naito et al., 2003; Shin'oka et al., 2001), and 




Cellular products for treatment of myocardial 
infarction 
 
These products are used to prevent heart failure and 
shorten the recovery period after myocardial infarction. 
All these products are in the clinical trial stage. The 
institutes involved in development of these products are 
Genzyme Biosurgery (USA) with cooperation of Myosix 
(France) (Hagege et al., 2006), Diacrin (USA) (Pagani et 
al., 2003), BioHeart Inc (USA) (the product under trial is 
MyoCell (Smits et al., 2003)), Osiris Therapeutics, Inc 
(USA) (the product under trial is Provacel (Hare,  2006)), 
Neuronyx (USA) (the product under trial is Human Adult 
Bone Marrow Derived Somatic Cells [hABM-SC] 
(Neuronyx, 2006)), the German universities including 
Johann Wolfgang Goethe-University Frankfurt (Scha-
chinger et al., 2004; Britten et al., 2003), University of 
Frankfurt (Assmus et al., 2002), University of Rostock 
(Stamm et al., 2003), Heinrich-Heine-University of 
Duesseldorf  (Ghodsizad   et   al.,   2004;  Strauer  et  al.,  




2002), and Hanover Medical School (Wollert et al., 2004), 
Instituto de Ciencias del Corazón (Spain) (Fernández-
Avilés, 2006), Texas Heart Institute (USA) (Perin et al., 
2003), Seoul National University (South Korea) (Kang et 
al., 2004), University School of Medical Sciences, 
Poznan (Poland) (Siminiak et al., 2005), and Russian 
State Institute for Transplantation (Belenkov et al., 2003). 
 
 
Tissue engineered products for treatment of diabetes 
 
These products are applied for better control of diabetes 
and reduction of morbidity and mortality of this disease. 
They are produced by processing of pancreatic islet cells 
and are in the clinical trial stage. The institutions dealing 
with these products include AmCyte (USA) (AmCyte 
Inc,), Living Cell Technologies (Australia) (the product is 




Tissue engineered liver products 
 
These products are aimed to be used in acute liver failure 
that leads to a high mortality in a few days. All these 
products are in the clinical trial stage including 
Extracorporeal Liver Assist Device (ELAD): the study on 
this product started by Vitagen company (USA) (formerly 
called Hepatix) and is continued by Vital Therapies (USA) 
(Millis et al., 2002; Millis et al., 1999; Ellis et al., 1996; 
Sussman et al., 1994); HepatAssist: this product was 
initially developed by Circe Biomedical (USA) but has 
been handed over to Arbios Systems (USA) (Demetriou 
et al., 2004; Watanabe et al., 1997; Demetriou et al., 
1995); Bioartificial Liver Support System (BLSS) by 
Excorp Medical (USA) (Mazariegos et al., 2002; Maza-
riegos et al., 2001; Kuddus et al., 2002); and Modular 
Extracorporeal Liver System (MELS) by Hybrid Organ 
(USA) (Sauer et al., 2003b; Sauer et al., 2003a). 
 
 
Tissue engineered neural products 
 
All these products are in the clinical trial stage including 
HuCNS-SC cells by StemCells, Inc (USA) for treatment of 
Infantile or late infantile neuronal ceroid lipofuscinosis 
(NCL) (StemCells Inc, 2006); dopamine-producing cells 
with proprietary name of Spheramine for treatment of 
Parkinson’s disease by cooperation of Titan Pharma-
ceuticals (USA) and Schering AG (USA) (Grosset and 
Grosset, 2005; Bakay et al., 2004). The products on 
clinical trial for application in spinal cord injuries include 
activated macrophages with the proprietary name of 
ProCord by Proneuron Biotechnologies (USA) (Knoller et 
al., 2005), olfactory ensheathing cells by Capital 
University of Medical Sciences (China) (Huang et al., 
2003)   and  Griffith  University  (Australia)  (Feron  et  al.,   




2005), Schwann cells by Tehran University of Medical 
Sciences (Iran) (Saberi et al., 2006), and bone marrow 
stem cells by three organizations including Institute of 
Experimental Medicine (Czech Republic) (Syková et al., 
2006), Inha University College of Medicine (South Korea) 
(Park et al., 2005), and the Hematology and Hemothe-
rapy Service of São José dos Campos (Brazil) (Callera 
and do Nascimento, 2006). 
 
 
ESTIMATION OF MARKET VOLUME 
 
According to the fact that tissue engineered products can 
be used for treatment of a wide spectrum of diseases and 
they are promised to be more curative than other 
therapeutic modalities, they possess a good marketing 
potential. The market potential is estimated according to 
the incidence and prevalence of the target disease, cost 
of current therapies, and availability and ease of appli-
cation of tissue engineered products. As mentioned 
above, skin and cartilage products are approved for 
clinical application and are commercially available. There 
is a high demand for these products in countries where 
they are available. It is anticipated that other products 
receive the approval of regulatory bodies and come onto 
the market in near future. According to the U.S. 
Department of Health and Human Services, the potential 
worldwide market volume for tissue engineered products 
was more than $300 billion in 2005 and will be $500 
billion in 2010 (Anon, 2006a). 
 
 
Market for tissue engineered skin products 
 
Cutaneous wounds are managed by traditional dressings, 
and advanced modalities such as antibiotics, growth 
factors and tissue engineered products. In 2001, the 
potential annual market volume for treatment of cutane-
ous wounds was estimated to be $6.25 billion worldwide, 
of which 10 - 12.8% ($625-800 million) belonged to the 
tissue engineered products. But, the manufacturers could 
only supply 2.5 - 3.2% ($20 million) of the worldwide 
demand (Hüsing et al., 2003; Anon, 2001b). The high 
difference between the potential demand and supply is 
due to the low production level and limited access of 
health care systems in different countries to these 
products. New figures show a rise in the actual demand 
of health systems for these modalities. For example, in 
2002, the annual sales of Apligraf was $23 million and 
that of Dermagraft was $4.5 million (Lysaght and 
Hazlehurst, 2004).  
The retail price is an important factor that should be 
considered when dealing with these modalities. It varies 
from $9.92-20.85 for each square centimetre (Jones et 
al., 2002; Bello et al., 2001; Monstrey et al., 1999; Still, 
Jr. et al., 1994), which is far more expensive than banked 
skin obtained from deceased donors. Banked skin is 





(Jones et al., 2002; Monstrey et al., 1999; Parente, 
1997). But, engineered products decrease the need for 
medication, dressing changes and nursing care, and the 
number of operations, which decrease the overall cost of 
the wound care (Parente, 1997).  
 
 
Market for tissue engineered cartilage products 
 
According to the 2002 report of CONCORD Corporate 
Finance Research (Anon, 2002b) about 20 million people 
are suffering from cartilage defects and injuries world-
wide. Also, the worldwide incidence of arthrosis is about 
25 - 20 million cases according to the 2001 estimation of 
Landesbank Baden-Württemberg Equity Research 
(Anon, 2001b). Accordingly, the worldwide annual market 
volume for cartilage repair was estimated to be $6.5 
million in 2001 and $25 million in 2011 (Anon, 2001b). 
But the actual worldwide annual sales for tissue engin-
eered cartilage products were reported to be around $40 
million (Hüsing et al., 2003). The difference is due to the 
limited supply of these products. But the other point is 
available products are only suitable for repair of particular 
cartilage defects. Different products are needed for 
regeneration of other types of cartilage injuries, which if 
engineered, increase the annual sales to $300 million-1 
billion only in the US (Russell and Cross, 2001).  
 
 
Market for tissue engineered bone products 
 
The target market for the engineered bone products 
include 10% of cases with bone fractures that could not 
be properly managed by the standard modalities (1.5 
million cases worldwide each year), maxillofacial and 
periodontal surgeries (4.5 million cases worldwide each 
year), and osteoporosis and bone tumours (300 million 
cases worldwide each year). In 2002, it was estimated 
that the bone repair market volume of those cases who 
are not suitable candidates for bone autograft will be 
around $300 million worldwide (Hüsing et al., 2003; Bock 
et al., 2003).  
 
 
Market for cardiovascular products 
 
Annually, 720 - 880 thousands coronary artery bypass 
operations are conducted in Europe and US (Hüsing et 
al., 2003). In 30% of these operations, a suitable 
autologous vessel cannot be harvested from the patient. 
This necessitates the use of synthetic prostheses. The 
maximum 5-year rate of patency of these prostheses is 
40-50% (Baguneid et al., 2006). Tissue engineered 
vascular products are suitable for these patients. The 
annual market volume of vascular substitutes is esti-
mated to be $1.5 billion (Szycher, 2002). As cell therapy 
protocols have not been approved by regulatory bodies 





diseases and their exact indications and contraindications 
are yet to be determined, estimation of market volume for 
these products may not yield an accurate figure. How-
ever, a rough evaluation of the potential cell therapy 
market for myocardial infarction estimated that the 
volume will be $2 million in US (Kuiters and Doering, 
2005).  
In regards to the heart valves, it should be noted that a 
tissue engineered product that can be used in a clinical 
trial has not been achieved in majority of studies. 
Nonetheless, estimation of market volume for these 
potential products is needed as heart valves are believed 
to be one of the major tissue engineered products. 
According to the published reports, the sales rate of 
these valves in 2001 amounted to $830 million (Hüsing et 




Market of tissue engineered products for treatment of 
diabetes 
 
According to the published reports, the worldwide number 
of diabetic patients was 170 million in 2000 and will 
increase to 360 million in 2030 (Wild et al., 2004). The 
indications of current tissue engineered products aiming 
to control diabetes have not been precisely defined yet. 
Depending on the results of current clinical trials, these 
products may be used in all diabetics or a particular 
percentage of patients who do not respond to conven-
tional modalities. A British report states that the latter 
include around 3% of insulin-dependent patients (Smith 
and Gale, 2005). In 2000, International Diabetes Federa-
tion estimated that the number of insulin-dependent 
diabetics was 5.3 million worldwide (Anon, 2000). If 3% of 
these patients benefit from tissue engineered products 
and the cost is $15000 per patient (Anon, 2006c), the 
estimated worldwide market volume for these products 
will be $2.4 billion. But, in another assessment, the 
volume was estimated to be $2 billion for just the US 
market (Anon, 2003a).  
 
 
Market for tissue engineered liver products 
 
According to the study performed for Vital Therapies, in 
2003 around 21000 patients were eligible to use liver 
substitute manufactured by this company (Anon, 2004). 
This figure exceeds the number of patients eligible for 
liver transplantation in the same year (Anon, 2005a). The 
report estimates that the annual market volume for liver 
substitute tissue engineered products will be around 
$1.08 million (Anon, 2004).  
 
 
THE SCIENCE BEHIND TISSUE ENGINEERING 
 
As it was mentioned above, tissue engineering is a 
multidisciplinary field that benefits from different  scientific  




areas including cellular science, biomolecules, biomate-
rials, manufacturing technology, biomechanics and 
informatics. This section has been adapted from the 2003 
report of SPRU Science and Technology Policy 






The field of cellular science plays important functions for 
tissue engineering including: (1) Identification, control and 
modification of the cellular behaviour in response to 
different factors and conditions. The tools needed to deal 
with this function are cellular biology, extracellular matrix 
biology, developmental biology and physiology, and 
immunology. The methodologies needed are genomics 
and proteomics. (2) Identification of suitable cell sources 
to be used in the tissue engineered constructs. This is an 
important field that has been extensively studied. The 
cells can be obtained as autologous, allogeneic, or 
xenogeneic. The cells can be obtained from adult, foetus 
or embryo and may be used with or without in vitro 
manipulation. (3) Identification and control of the factors 
that influence cellular proliferation and differentiation. 
Cells are the main structural units of tissue engineered 
constructs; therefore high numbers of cells are needed 
for productions of these constructs at the industrial level. 
One of the best ways to fulfil this demand is manipulation 
of the cellular proliferation machinery. One of the main 
reasons that stem cells attracted so much attention in 
recent years is their high proliferative capacity. But, as 
they are undifferentiated, they need to be induced to 
differentiate into the desired phenotype. Therefore, cellu-
lar differentiation has been recognized as an important 





Biomolecules are components of the biological systems 
that can modify the cellular behaviour. Preparation and 
delivery of biomolecules to the target cells are important 
parameters in tissue engineering. Biomolecules can be 
synthetically manufactured and delivered to the cells, or 
the cells can be modified to produce their required 
biomolecules themselves. Gene therapy is related to 
tissue engineering for this purpose. Delivery of biomole-
cules is another important field. These molecules can be 
just simply added to the cell culture medium, or for a 
more controlled and timely release, delivered through 
extracellular matrix components. Also, encapsulation with 
materials that allow controlled-release of these molecules 





Biomaterials are used for engineering of bioscaffolds on 
which the seeded cells will proliferate, migrate  and  diffe- 




rentiate. Bioscaffolds will determine the shape and 
mechanical properties of the construct. They are not only 
carriers of the seeded cells, but also bridges through 
which the cells in the recipient site can migrate and 
accelerate the healing process. Bioscaffolds can be used 
for delivery of biomolecules to the site of injury as well. 
The important factors that should be considered for 
engineering of bioscaffolds are their shape and mecha-
nical properties, biocompatibility and cell attachment 
properties, biodegradability and the properties of their 
biodegradation products. Different natural, synthetic and 






Different technical aspects should be taken into account 
when a product is aimed to be manufactured at industrial 
level. These considerations may not be necessary for 
laboratory level production of the same products. For 
example, bioreactors can be employed for mass pro-
duction of cells and 3-dimentional tissue engineered 
products. Bioreactors enable employment of mechanical 
forces and scheduled delivery of biomolecules for cell 
culture. Preservation of the engineered products is 
another issue. The shelf life of the product and its storage 
condition are very important. For example, a product 
which can be stored in room temperature is much cheap-
er than a product that should be stored frozen. As 
freezing is necessary for storage of most products, 






Some organs such as heart, blood vessels, cartilage and 
bone have mechanical functions in the body. Therefore, 
the mechanical properties of products aiming to be used 
in these organs should be taken into account as they 
affect the functional outcome of the products. The other 
issue is these properties may change after implantation 
and interaction with cells and biomolecules in the 





Informatics can help to anticipate the cellular behaviours 
in different conditions. Currently, informatics has 
progressed in fields of genomics, proteomics and even 
microarrays, but the fields of cell, tissue, physiome 
(physiome is a science that deals with the physiologic 
dynamic of a healthy organism) and commercial informa-
tics are still in a very primitive stage. Tissue engineering 
will be greatly benefited from expansion and progression 





Keys to success 
 
According to what already have been pointed out, a 
number of factors needed for construction of a successful 
tissue engineering business model can be listed. But, 
according to the report of Fraunhofer Institute for 
Systems and Innovation Research (Germany) (Hüsing et 
al., 2003), amongst all factors, the most important one is 
relevant knowledge. Many companies start their activities 
in this filed merely by a knowledge of cell and tissue 
culture while this multidisciplinary filed needs knowledge 
in biomaterials, extracellular matrix, biomolecules, and 
quality control at the same time. Lack of clinical 
knowledge is another problem in these companies. 
Logistical flexibility is another issue because the time of 
manufacturing of some products should be properly 
synchronized with the time of surgical operation. The 
other strategy that is sometimes ignored is direction of 
research activities to fulfil the market demands. The 
scientists may get involved into interesting studies which 
are far away from the market demands. This issue 
frequently occurred in Europe. For example, not much 
has been done in critical areas such as length of 
manufacturing, storability, shelf life, and ease of handling 
of the products. Economists and merchants should be 
consulted for identification of commercially important 




WORLDWIDE APPROACH TO TISSUE ENGINEERING 
 
Most tissue engineering studies and companies are 
concentrated in the United States. But other countries 
have also realized the importance and the present 
situation of this field and initiated directed and focused 
activities in tissue engineering. In 1995, only 5% of active 
tissue engineering companies were non-American, but 
this figure rose to 46% in 2002 (Anon, 2006a). In regards 
to the technological capabilities and advancements, 
Europe and Japan can be considered as the second and 
third tissue engineering poles after US. Below, the 
strategies adopted by different countries to get benefit 





Most investments in this field have been made by private 
companies. According to the published reports, from 
early 90s to 2002 the investment of private companies on 
this field amounted to $4.5 billion (Lysaght and 
Hazlehurst, 2004), and government’s investment from 
1998 to 2001 amounted to only $250 million (McIntire et 
al., 2002). U.S. Department of Health and Human 
Services states that this trend should be corrected (Anon, 
2006a). This department estimates an annual market 





it as the first industry of new millennium and a deter-
minative technology. As the anticipated time of entering 
to the market is not long for a wide range of tissue 
engineered products, a focused investment and organiz-
ed direction of financial and human resources and 
research activities has been recommended for gaining 
access to this market. Department of Health reiterates 
that private sector only invests on a few products, which 
require somewhat similar and easily available technolo-
gies. But, many products need complex technologies that 
necessitate integration of major scientific areas — such 
as medicine, biology, biochemistry and biomaterials — at 
different levels. The integration can be optimized if the 
conditions allow physical and temporal closeness of 
scientists in appropriate clusters. In addition, the high 
industrial orientation of tissue engineering requires very 
close cooperation of academic and industrial sectors for 
sending the products to the market in a short period of 
time. So far, the applied aspect of these products were 
the focus of most American studies and less was done in 
regards to basic and fundamental aspects and under-
standing of the involved mechanisms in tissue 
engineering (McIntire, 2003). Governmental support is 
necessary for leading scientists to deal with the latter 
issues. US government has recognized tissue engineer-
ing as a profitable industry and planned to increase the 
growth rate of this sector in all its aspects. For example, 
to expedite the approval process of tissue engineered 
products, the Office of Combination Products (OCP) has 
been established in FDA in 2002. In 2006, Department of 
Health proposed the establishment of a new institute, the 
Federal Initiative for Regenerative Medicine (FIRM) 
(Anon., 2006a), which should be highly supported by the 
government for up to 20 years to make a proper link 
between the academic and industrial sectors. Currently, 
the tissue engineering studies are made on an individual 
basis in the United States, e.g. the studies on myocardial 
repair are performed in the departments of cardiology 
and those of bone tissue repair are performed in the 
departments of orthopaedics. But these have a lot in 
common, and therefore, their close interaction is neces-
sary to solve the common questions more efficiently. One 
of the main functions of FIRM will be establishment of a 
closer inter-sector cooperation. At this time, award of 
grants, legislation and other issues of tissue engineering 
is dealt with by different organs such as Department of 
Health and Human Services (including NIH and FDA), 
Department of Defence (including DARPA), NASA, 
Department of Commerce, the White House Office of 
Science and Technology Policy, the President’s Council 
of Advisors on Science and Technology, and the National 
Science Foundation (NSF). It was proposed that FIRM 
takes over all these functions. To do so, FIRM should 
employ members from both academia and industry. The 
proposed expertise of FIRM members is engineering 
(different branches), medicine (different specialties), 
biology (cellular, developmental, structural, vascular, and  




computational), nanotechnology fabrication, immunology, 
biomaterial, economy, education, sociology, psychology, 
ethics, biochemistry, and chemistry (Anon, 2006a).  
This proposal of a long-term support of tissue engineer-
ing by the government is based on previous similar 
support of other technologies. For example the status of 
semiconductor technology in late 1980s and early 1990s 
was similar to the current status of tissue engineering. 
But a timely $2 billion government investment and 
establishment of Semiconductor Manufacturing Techno-
logy Consortium (SEMATECH) led to the growth of this 
industry from an annual amount of $8 billion to $170 






Germany, UK, and France are the most active European 
countries (in descending order) in the field of tissue 
engineering. The other active countries are Scandinavia 
and Benelux (Bock et al., 2005). Government provides 
most funding in Europe; therefore, more attention has 
been paid to fundamental and basic studies (McIntire, 
2003). But most centres working on tissue engineering 
are young and have not grown to a suitable size yet. The 
annual sales of these organizations, which are mostly 
concentrated on autologous products, do not exceed a 
few million dollars. The active institutes are working on a 
wide range of research topics. This necessitates 
establishment of a central organization, similar to US, for 
needs assessment and definition of national or European 
research priorities. Tissue engineering activities have 
extended to the hospitals and tissue banks as well. The 
research hospitals closely collaborate with academic 
tissue engineering centres and have focused on develop-
ment of products that have not mostly reached to the 
clinical trial stage yet. Non-research hospitals have 
concentrated on optimization of the existing products, or 
produce tissue engineered products for their own use. 
Tissue banks mostly work on decellularization of 
allogeneic tissues for using them as scaffolds for culture 
of autologous cells (Bock et al., 2005). In general, the 
collaboration between academic and industrial sectors is 
not as much as expected and research into issues with 
industrial and commercial values is delayed (Senker and 
Mahdi, 2003). In Europe, the emphasis on the strategic 
value of tissue engineering is not as strong as US but, 
the process needed for a product to receive marketing 
approval is shorter than United States. Similar to US, due 
to lack of a central organizing institute, the activities of 
different groups are not coordinated (Hüsing et al., 2003; 
Bock et al., 2003). But there are initiatives attempting to 
define national or even European policies to create a 
focused and coordinated environment to accelerate the 
growth of this new technology. One of the main obstacles 
of marketing of tissue engineered products in Europe was  




different regulatory issues in European countries. 
Therefore, in 2002, European Union started a compre-
hensive program to determine and unify the existing 
regulations in different countries. After three years of 
study and adoption of different and sometimes conflicting 
strategies, in 2005, European Commission has finalized 
its regulatory proposal for submission to the European 
Parliament, the Economic and Social Committee and the 
Committee of the Regions (Anon, 2005c; Kaiser, 2006). 
According to this proposal, tissue engineered products 
together with gene and somatic cell therapies will be 





This section is adapted from the report of the United 
Kingdom’s Royal Academy of Engineering Mission to 
Japan (Williams, 2003): The government has heavily 
invested in this technology and established several 
advanced centres. Therefore, in Japan, similar to Europe, 
basic and fundamental studies are performed in the field 
of tissue engineering. This provides a strong back-ground 
necessary for manufacturing of complex products 
(McIntire, 2003). This investment is the result of 
government’s decision to increase the volume of biotech-
nology products from $10 billion to $212 billion (more 
than 20 times) in a 10-year program (Anon, 1999). In 
2001, a budget of $800 million was allocated to tissue 
engineering and the closely related fields of genomics, 
stem cells, and bioinformatics. In 2003, Ministry of 
Education, Science and Technology was asked to spend 
$400 million on strategic initiatives to expedite the 
process needed for new tissue engineered and genetic 
therapeutic modalities to move from the research 
laboratories to the clinical practice. Establishment of 
strong infrastructures such as Tissue Engineering 
Research Centre (TERC) and Institute of Biomedical 
Research and Innovation (IBRI) have also been noted.  
Tissue Engineering Research Centre (TERC) is 
affiliated to the National Institute of Advanced Industrial 
Science and Technology (AIST). Due to high demand for 
close interaction of tissue engineering with commercial 
and industrial sectors, TERC has been established under 
close supervision of the Ministry of Economic, Trade and 
Industry with an initial budget of $26 million and an 
annual running budget of $10 million.  
Institute of Biomedical Research and Innovation (IBRI) 
was established with an initial budget of $110 million and 
an annual running budget of $40 million. The main 
research themes of this institute are tissue engineering 
applications, clinical research for production of medicinal 
products, and medical equipment. IBRI is located in Kobe 
city that has been transformed into a “Medical Industry 
City”. This city has been designed by the Centre for 
science, technology and economic development of 





previous successful American models (Mathieson, 2005). 
Next to IBRI, the RIKEN (RIKEN is an abbreviation of 
“Institute of Physical and Chemical Research” in Japan-
ese language) Centre of Developmental Biology is built, 
which is run by an annual budget of $50 million 
concentrating on areas such as aging, environment and 
information technology (Anon, 2006b). Kobe International 
Business Centre, Translational Research Informatics 
Centre, Biotechnology Training and Research Centre, 
and Biomedical Accelerator (Biomedical Accelerator is 
aimed to help commercialization of biological research 
findings) are located in close proximity to IBRI and 
RIKEN Centre for Developmental Biology. This campus 
creates an environment in which the scientists with the 
knowledge needed for successful manufacturing of 
industrial biological products communicate more closely 
and efficiently. This well-thought solid infrastructure 
makes Japan one of the most successful manufacturers 
of biological products, and especially, tissue engineered 






In a study performed by University of Toronto’s Joint 
Centre for Bioethics (Greenwood et al., 2006), the status 
of tissue engineering was assessed in 31 low- and 
middle-income countries. These countries were classified 
according to 4 criteria including: (1) existence of a 
national plan for promotion of tissue engineering and 
government’s investment in this sector, (2) existence of 
marketable tissue engineered products or services (e.g. 
cartilage repair with autologous cells), (3) existence of 
active private companies in this field, (4) existence of 
tissue engineering academic institutions and/or publica-
tions. The countries possessing all four criteria were 
Brazil, China, and India. Argentina, Bulgaria, Chile, 
Malaysia, Mexico, Poland, Slovakia, South Africa, and 
Thailand had criteria 2-3. Columbia, Cuba, Egypt, and 
Russia had criteria 3-4; and Belarus, Hungary, Iran, 
Latvia, Lithuania, Pakistan, Romania, Saudi Arabia, 
Serbia, Turkey, Ukraine, Vietnam, Moldova, Philippine, 
and Uganda possessed only the last criterion.  
This study shows that Indian and Chinese approach to 
tissue engineering is very well planned. This compre-
hensive look to tissue engineering will lead these pioneer 
countries to capture the potential markets in the region. 
The long-standing experience of China to penetrate into 
different worldwide markets will help this country to 
expand into the international market of tissue engineered 
products as well. In Middle East, Iran, Turkey, Saudi 
Arabia, and Pakistan have adopted similar approaches, 
mainly academic, to this field. If any of these countries 
starts a comprehensive initiative for setting up of the 
required infrastructure, it may be able to win the Middle 





EFFECTS ON NATIONAL DEVELOPMENT 
 
In 2002, United Nations Economic and Social 
Commission for Western Asia in cooperation with 
International Labour Organization held a meeting in 
Beirut, in which 170 representatives from different Arabic 
countries participated (Anon., 2002). This meeting was 
aimed to identify and determine the best approach for 
regional capacity building in new technologies to increase 
the employment rate, establish sustainable development, 
and alleviate poverty in Arab countries. Final report of this 
meeting states that adoption of a suitable national 
strategy for establishment of a planned development in 
science, technology and special initiatives is a necessity. 
For this purpose, the first important step would be to 
identify new technologies, which according to the existing 
knowledge and resources, expected outcomes, and the 
trend of international development, could be considered 
as high priorities for national economic and social 
developments. In this report, it was emphasized that the 
countries, which adopt a better approach to the four novel 
technologies of informatics, biotechnology, genetic engin-
eering, and biomaterials, will develop better capacity for 
economic and social developments. In regards to 
biotechnology, it was proposed that Arab countries invest 
in making a strong infrastructure for plant and 
pharmaceutical biotechnology, tissue engineering, and 
biocomputer technology (biocomputers are new genera-
tion of computers in which biologic materials are used to 
increase the speed of data processing).  
In 2006, the National Security Research Division of 
RAND Corporation published the report of a study funded 
by the US National Intelligence Council, the Intelligence 
Technology Innovation Centre (ITIC), and the Depart-
ment of Energy (Silberglitt et al., 2006). This study 
predicts the status of technology in different countries up 
to 2020 according to the current trend of technology 
development plans in those countries. The society was 
divided into 12 economic sectors including water, food, 
land, population, governance, social structure, energy, 
health, economic development, education, defence and 
conflict, and environment and pollution. It has been 
mentioned that tissue engineering impacts four sectors of 
population, governance, health, and economic develop-
ment (one third of the economic structure). On the other 
hand, the issues that can hinder the rate of a country’s 
development have been classified into eight groups of 
rural economic development, economic growth and 
international commerce, public health, individual health, 
resource use and environment health, military and 
warfighters of the future, homeland security and public 
safety, and governance and social structure. The report 
emphasizes that tissue engineering will have positive 
impacts on three (more than one third) issues including 
economic growth and international commerce, individual 
health, and governance and social structure. 
In this report, tissue engineering has been recognized 
as one of the  top  16  applications,  which  represent  the  




countries capacity for technology implementation in 2020. 
According to the current trend of technology develop-
ment, it was anticipated that except North America, 
Western Europe, Israel, Japan, North Korea, and 
Australia, other countries will not be able to acquire this 
technology at a commercially profitable level until 2020. 
Lack of success of other countries in acquiring this 
technology was attributed to the high cost, unbalanced 
investment in research and development (R&D), legisla-
tive and political barriers, inappropriate infrastructure, 
educational problems, particular social values and public 
opinions, and social stability. But the study predicts that, 
until 2020, most countries will be able to utilize the tissue 
engineered products, which increases the worldwide 
demand and makes tissue engineering a highly profitable 
technology.  
It has been reiterated that establishment of required 
infrastructure for advanced technologies will enable many 
countries to have access to them. For example, Kenya 
could acquire the technology for production of GM crops 
in 2005 by proper investment, planning and 
establishment of a suitable infrastructure. Therefore, 
establishment of infrastructure and capacity building was 
recognized more and more important than training of 
skilled and knowledgeable people. In this report, training 
of scientists and technicians without establishment of 
proper infrastructures and production units has been 
counted as a waste of resources. For example, Philippine 
has been noted in which many of medical doctors choose 
to go to the nursing schools to increase their chance of 
employment in an overseas country (Choo, 2003).  
In general, a detailed look at tissue engineering shows 
that expansion of this technology can help development 
of academic, industrial, and professional activities in the 
following fields: enzymes production, recombinant protein 
production especially growth factors, antibody engineer-
ing, culture media production, production of natural and 
synthetic polymers, engineering and modelling of 
bioscaffolds, engineering of chemicals for bioscaffolds 
assembly, transplantation immunology, genetic 
engineering, live cells and tissues preservation and 
transportation technologies, engineering of manufacturing 
equipment, legislation for proper production, distribution 
and use of these products, standardization of production, 
ethics, training of doctors and nurses for application of 
tissue engineered products, and national and 





Tissue engineering is a new technology which can help 
management of a number of previously unresolved health 
problems. The estimated market volume for tissue 
engineered products is promising but capture of this market 
needs an organized and timely investment to build a strong 
infrastructure. This infrastructure can advance the national 
development in developing countries. 
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